Febuxostat 40 mg

DRUG5 trials

Sponsors

Ardea Biosciences, Inc., National Defense Medical Center, Taiwan, JW Pharmaceutical, Ain Shams University

Conditions

Carotid Intima- Media ThicknessGoutHealthyHyperuricemiaLeft Ventricular Diastolic DysfunctionMetabolic Syndrome

Phase 1

RDEA3170 and Febuxostat Drug Interaction Study

CompletedNCT01883167

Ardea Biosciences, Inc.Healthy

Start: 2013-06-30End: 2013-12-31Updated: 2014-01-09

Febuxostat Effect on Chronic Kidney Disease Progression And Carotid Intima-Media Thickness

CompletedNCT06997952

Ain Shams UniversityCarotid Intima- Media Thickness

Start: 2024-05-24End: 2024-08-24Updated: 2025-05-31

Phase 2

RDEA3170 and Febuxostat Combination Study in Gout Subjects

CompletedNCT02246673

Ardea Biosciences, Inc.Gout

Start: 2014-10-31End: 2016-02-29Updated: 2017-07-27

Phase 3

A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patients

JW PharmaceuticalGout

Start: 2023-03-14End: 2025-08-31Target: 588Updated: 2023-04-18

Phase 4

Urate Lowering Therapies and Left Ventricular Diastolic Dysfunction

National Defense Medical Center, TaiwanHyperuricemia, Left Ventricular Diastolic Dysfunction, Metabolic Syndrome

Start: 2020-02-01End: 2021-12-31Target: 120Updated: 2020-04-28

Related Papers

Higher Febuxostat Exposure Observed in Asian Compared with Caucasian Subjects Independent of Bodyweight.

2020-09-195 citations

Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with febuxostat in adults with gout: a phase IIa, open-label study

RMD Open2018-04-0113 citations

Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study

RMD Open2018-02-0139 citations